Rheumatology, Ramón y Cajal University Hospital.
Interested in idiopathic inflammatory myopathy and interstitial lung diseases associated to CTD.
Mar 28, 2023 • 7 tweets • 3 min read
RITAZAREM ➡️ Rituximab (RTX) versus azathioprine (AZA) for maintenance of remission for patients with ANCA-associated vasculitis (ANCA-AV) and relapsing disease.
ard.bmj.com/content/early/…
Design:
- Open label, randomized.
- Patients with relapsing GPA or MPA, ANCA +.
- Induction phase (4 months): RTX 375 mg/m2x4 doses.
- Maintenance phase (4-24 months). Randomized to RTX (1 gram every 4 months, 5 doses) vs AZA (2 mg/kg).
- Follow-up phase (12-24 months).
Mar 15, 2020 • 7 tweets • 2 min read
Hidroxychloroquine (HQ) basics for non-rheum in COVID-19:
- Increases endosomal pH, interferes with the glycosylation of cellular receptors of SARS-CoV2.
- In vitro activity in SARS-CoV and SARS-CoV2.
Proposed dosing (COVID-19): 400 mg bid 1 day➡️200 mg bid 4 days. Longer tx?
Usually very well tolerated, most of adverse effects after months/years of therapy!
Better profile compared to chloroquine.
- Retinopathy. After long time-exposure, risk factors: > 5 mg/kg/day, renal insufficiency, tamoxifen use, obesity...
Not a problem for short term.
